ClinicalTrials.gg
DrugBiological

Ublituximab clinical trials

Also written TG-1101, BRIUMVI and TG-20.

studies test it
37
open now
11
in phase 3
9
first study started
2008

How each study uses ublituximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ublituximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Dec 2022 · BRIUMVI · BLA 761238 (FDA, Drugs@FDA)
European Union
31 May 2023 · Briumvi · EMEA/H/C/005914 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ublituximab
34
LFB-R603
6

Brand

BRIUMVI
5

Development codes

TG-1101
20
TG-20
3
TGTX-1101
3

Studies by the year they started

37 studies that test it; most in 2026 (8)

Studies that test ublituximab, by start year
YearStudies
20081
20122
20131
20141
20152
20163
20174
20194
20202
20213
20221
20232
20253
20268

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
10
Phase 2
20
Phase 3
9
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 23 · Other 14

TG Therapeutics, Inc. (22) · City of Hope Medical Center (2) · Johns Hopkins University (2) · Jennifer R. Brown, MD, PhD (1) · University of Colorado, Denver (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Jonathan Santoro (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)

Often tested with

Tested in the same studies.

Umbralisib (12) · Acalabrutinib (1) · Fingolimod (1) · Cosibelimab (1) · Tazemetostat (1) · Lenalidomide (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test ublituximab, phase 3 first.

Studies

Open first, then newest update. How each study uses ublituximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 37

See all 37 studies that test ublituximab →

Given beside what is tested · 7 — ublituximab is usual care or a partner of the new treatment

Codes

What other systems call ublituximab · ClinicalTrials.gg INT000673

  • MeSH (NLM) C000619007ublituximabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) U59UGK3IPCUBLITUXIMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q7876570ublituximabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C91078UblituximabOne source FDA
  • DrugBank DB11850One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.